Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization
Patients with PAD after lower extremity revascularization meeting fragile criteria are at higher risk of ischemic complications and bleeding. Rivaroxaban reduces ischemic risk and increases bleeding regardless of frailty status. These data may assist in personalization of antithrombotic therapy in fragile population.
Authors
- Mario Enrico Canonico (ORCID: https://orcid.org/0000-0001-8452-7464)
- E. Sebastian Debus
- Manesh R. Patel (ORCID: https://orcid.org/0000-0002-2393-0855)
- Eva Muehlhofer (ORCID: https://orcid.org/0000-0001-8213-232X)
- Judith A. Hsia (ORCID: https://orcid.org/0000-0002-3413-7836)
- Warren H. Capell (ORCID: https://orcid.org/0000-0002-1073-3721)
- J. Ycas (ORCID: https://orcid.org/0000-0001-7783-1273)
- Lloyd Haskell
- Scott D. Berkowitz (ORCID: https://orcid.org/0000-0002-9428-4408)
- Sonia S. Anand (ORCID: https://orcid.org/0000-0003-3692-7441)
- Cecilia C. Low Wang (ORCID: https://orcid.org/0000-0001-8557-5417)
- Mark R. Nehler (ORCID: https://orcid.org/0000-0003-1012-7307)
- Rupert Bauersachs (ORCID: https://orcid.org/0000-0001-6192-1741)
- Marc P. Bonaca (ORCID: https://orcid.org/0000-0002-9860-3584)
Institutions
- Twitter (United States) (US)
- Universität Hamburg (DE)
- Johannes Gutenberg University Mainz (DE)
- Population Health Research Institute (CA)
- Cardiovascular Center Bethanien (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Duke Medical Center (US)
- Agaplesion Bethanien Krankenhaus (DE)
- Meridian Clinical Research (US)
- Janssen (United States) (US)
- Bayer (Germany) (DE)
- University of Colorado Denver (US)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1016/j.jacc.2024.05.060
- Citations
- 10
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 5.73
Funders
- Bayer Corporation
- Janssen Pharmaceuticals